Iambic Therapeutics, Inc.
IAM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001997038
In the last 90 days, Iambic Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysLast 90 days, $11.5M in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.06M
- Shares sold short
- Change
- +1.06M
- +100.0% vs. previous
- Days to cover
- 1.17
- At average daily volume
Superinvestors holding IAM, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding IAM at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Iambic Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 (view filing)7:47 PM ET | Oct 16 | 3 days | Rachlin Evan LockwoodDirector | PPurchase | +718.8K | $16.00 | +$11.5M | +38.4%2.59M after |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in Iambic Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding IAM in 13F filings for Q2 2026.
Holders of 5% or more of IAM
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Iambic Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Qatar Investment Authority | 13G | 5.80%2.80M shares | New | Nov 9, 20261 filing | Nov 9, 2026 | SEC |